VivoSeq
Infectious Disease

Hepatitis B Virus Infection

28

Pipeline Programs↗

2

Active Trials↗

16

Companies Involved↗

Hepatitis B Virus Infection is an emerging landscape with 28 programs across 16 companies. The most active players are Regeneron, Eli Lilly, Johnson & Johnson. 10 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

50/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Regeneron logo

Regeneron

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2GSK logo

GSK

1 program

Phase 3K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 3Eisai logo

Eisai

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

90%

Small molecule

27 of 30 classified programs — the dominant modality here.

10%ALL OTHERSMonoclonal antibody27%Vaccine13%

Small molecule leads; the ring shows all 30 classified programs, each share of the total. Modality classified for 97% of 31 pipeline programs.

Analysis

Trial Status

6

clinical trials

Completed2 · 33%
Not yet recruiting1 · 17%
Terminated1 · 17%
Withdrawn1 · 17%
Recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection
Recruiting·GGigaGen, Inc.·Phase 1·NCT07024641·48 enrolled
A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses
Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT05897138·30 enrolled
Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection
Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT03312023·21 enrolled
Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV .
Completed·UUniversidad de Valparaiso·Phase 3·NCT02003703·107 enrolled
Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors
Terminated·SWOG Cancer Research Network·Phase 3·NCT03887702·4 enrolled
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
Withdrawn·—·Phase 2/3·NCT04044651

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)